echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Only 27 million imatinib was sold

    Only 27 million imatinib was sold

    • Last Update: 2021-08-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    1.


    1.


    According to the announcement, Sinopharm Yixin Pharmaceutical Co.


    The announcement stated that the company's imatinib mesylate tablets had passed the generic drug quality and efficacy consistency evaluation in May 2021


    Shanghai Modern Pharmaceutical stated that after the signing of this contract, Sinopharm Yixin still needs to complete the change of the relevant preparation marketing license holder, and will implement the transfer of raw material technology and the change of preparation production address.


    2.


    2.


    Public information shows that in the 4+7 volume procurement negotiations, Hausen’s imatinib mesylate tablets (0.


    In fact, the price of imatinib mesylate tablets has been adjusted in recent years


    According to data from Minai.


    3.


    3.


    According to the announcement, this time Sinopharm's single-minded transfer of imatinib mesylate-related technical projects is in line with the company's strategic development plan, which will help enrich the company's product battles in the field of anti-tumor and immunotherapy, and enhance Sinopharm Yixin's market competitiveness


    According to data from Zhongkang, the size of China's anti-tumor drug market in 2018 was 106.


    According to data released by the National Cancer Center in February 2018, the estimated number of new cases of malignant tumors in China is 3.


    Earlier, the state issued policies to support the development of anti-tumor drugs


    In fact, the field of anti-tumor drugs has always been the focus of innovative drug companies' research and development.
    In 2018, Hengrui ranked first with 29 trials
    .
    With huge market demand and favorable policies, major pharmaceutical companies are actively deploying their oncology drug pipelines
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.